(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(0.28%) $83.80
(-4.58%) $1.563
(0.16%) $2 346.30
(0.34%) $27.45
(0.96%) $929.30
(0.09%) $0.933
(0.14%) $10.97
(0.08%) $0.800
(0.02%) $92.18
@ $9.40
Issued: 14 Feb 2024 @ 13:07
Return: -34.52%
Previous signal: Feb 14 - 11:58
Previous signal:
Return: 1.68 %
Live Chart Being Loaded With Signals
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications...
Stats | |
---|---|
Today's Volume | 1.35M |
Average Volume | 1.20M |
Market Cap | 807.41M |
EPS | $0 ( 2024-02-22 ) |
Next earnings date | ( $-0.720 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.21 |
ATR14 | $0.0180 (0.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Catinazzo Thomas | Sell | 348 | Common Stock |
2024-03-27 | Bergstrom Donald A | Sell | 765 | Common Stock |
2024-03-27 | Rahmer Peter | Sell | 298 | Common Stock |
2024-03-27 | Adams Brian | Sell | 348 | Common Stock |
2024-01-29 | Rahmer Peter | Sell | 1 651 | Common Stock |
INSIDER POWER |
---|
87.68 |
Last 99 transactions |
Buy: 4 152 455 | Sell: 399 360 |
Volume Correlation
Relay Therapeutics, Inc. Correlation
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Relay Therapeutics, Inc. Correlation - Currency/Commodity
Relay Therapeutics, Inc. Financials
Annual | 2023 |
Revenue: | $25.55M |
Gross Profit: | $20.28M (79.37 %) |
EPS: | $-2.79 |
Q4 | 2023 |
Revenue: | $-1 000.00 |
Gross Profit: | $-1.38M (137 600.00 %) |
EPS: | $-0.680 |
Q3 | 2023 |
Revenue: | $25.20M |
Gross Profit: | $23.84M (94.59 %) |
EPS: | $-0.540 |
Q2 | 2023 |
Revenue: | $119 000 |
Gross Profit: | $-1.22M (-1 021.01 %) |
EPS: | $-0.810 |
Financial Reports:
No articles found.
Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators